相关实验视频
Updated: Jun 22, 2026

07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
雷斯是一种状特异性蛋白质,调解了突变猎素细胞毒性
Srinivasa Subramaniam1, Katherine M Sixt, Roxanne Barrow
1Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
概括
亨廷顿病 (HD) 病理局限于条纹体,这是由于突变的亨廷丁 (mHtt) 与条纹体特异性蛋白Rhes.之间的相互作用造成的. 结合Rhes诱导mHtt的sumoylation,导致细胞死亡,并解释了HD选择性脑区域的影响.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 亨廷顿病 (HD) 是由于在亨廷丁 (Htt) 中重复的多重氨酸导致的.
- 突变的亨廷丁 (mHtt) 无处不在表达,但HD神经病理主要影响状体.
- 这种神经病理选择性背后的分子机制仍然不清楚.
研究的目的:
- 为了研究在状体中亨廷顿病选择性神经病理学的分子基础.
- 确定与突变亨廷丁 (mHtt) 相互作用并以特定区域的方式对其毒性产生影响的蛋白质.
主要方法:
- 研究了突变的亨廷丁 (mHtt) 与小瓜核酸结合蛋白Rhes.之间的相互作用.
- 利用培养细胞来研究Rhes对mHtt的影响.
- 评估了由Rhes诱导mHtt的sumoylation及其随后对细胞毒性的影响.
主要成果:
- 确定了Rhes,一种选择性地局部化到条纹体的蛋白质,作为mHtt.的生理结合伙伴.
- 证明Rhes结合会在培养细胞中诱导mHtt的sumoylation.
- 显示Rhes诱导的mHtt化导致细胞毒性.
结论:
- 雷斯-mHtt相互作用为亨廷顿病中观察到的神经病理选择性提供了分子解释.
- 准Rhes或其与mHtt的相互作用可能为HD提供治疗策略.
相关概念视频
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Export of Misfolded Proteins out of the ER
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...

